Patient360

Patient360™, developed by ConcertAI, is the most comprehensive real-world oncology dataset available, designed to deliver deeply curated, multi-modal insights across the full patient journey. By linking electronic health records (EHR), claims data, genomics, social determinants of health (SDoH), and death date information, Patient360 provides research teams with a true 360-degree view of each oncology patient. With over 100 curated clinical variables per patient, the platform is built to support faster, more precise evidence generation for life sciences organizations, research teams, and healthcare stakeholders.

Patient360 is purpose-built for oncology research teams seeking to model outcomes, identify access gaps, track real-world treatment patterns, and generate evidence that reflects actual clinical practice rather than controlled trial conditions. The dataset spans community, academic, and integrated delivery network (IDN) treatment settings with catchment across all U.S. states, ensuring broad national representativeness across payer types and care sites.

Key Benefits

• Multimodality: Access the industry's largest real-world EHR oncology dataset, integrated with claims, genomic, and SDoH data for a comprehensive patient view.
• Curation: Benefit from rapid, machine-supported abstraction delivering 100+ clinical variables per patient, making the dataset research-ready from day one.
• Precision: Uncover in-depth insights and generate evidence on treatment, biomarkers, and outcomes across tumor types that reflect real-world practice.
• Representativeness: Data sourced from oncology practices across community, academic, and IDN settings with coverage across all U.S. states.

Core Capabilities

• Real-World Evidence Generation: Deeply curated EHR, claims, and SDoH data enables rapid cohort creation for targeted studies. Supports safety analyses, comparative effectiveness research, and patient profiling, with over 100 curated clinical variables per patient available on demand.
• Line of Therapy and Treatment Mapping: Longitudinal tracking from diagnosis through palliative care allows researchers to visualize treatment sequencing and transitions. Integrates labs, imaging, surgery, therapies, and outcomes to detect undertreatment, switching patterns, and gaps in care.
• Cohort Augmentation: Enables researchers to expand access to hard-to-find patients by adding individuals with specific biomarkers, therapies, or testing profiles. Supports NGS, PD-L1+, second-line and beyond, rare cancers, and other subpopulations, all curated to Patient360 standards.
• Multi-Modal Integration: Claims and SDoH data enrich EHR-only views, with linkage to more than 85% of patients from 2014 onward. The nationally representative population supports payer analysis, adherence tracking, access research, and socioeconomic insights.

Use Case Highlights

• Treatment sequencing: Reveals how patients transition between standard-of-care and novel therapies across multiple lines, uncovering real-world patterns and gaps in care.
• Timely therapy updates: Enables evaluation of how outcomes vary across treatments, populations, and in contrast to controlled clinical trials.
• Biomarker testing: Highlights the frequency, timing, and impact of diagnostic tests to support better understanding of treatment decisions and personalization.
• Economic burden: Quantifies the true cost of disease by tracking spend across therapy types, adverse events, providers, and payer categories.
• Clinical trial design: Refines study design by modeling inclusion and exclusion criteria against real-world cohorts to identify practical recruitment strategies.

Patient360™ Select — Featured Extension

Patient360 Select is a curated subset of the Patient360 dataset designed to rapidly expand patient counts for specific research needs without sacrificing data depth. It is ideal for trial optimization, natural history studies, and comparative effectiveness research, offering faster and more cost-effective access to richly curated cohorts in key oncology indications.

• Currently available indications: Bladder, Melanoma, Renal Cell Carcinoma, Hepatocellular, Gastroesophageal, Endometrial, and Glioblastoma.
• Deep Clinical Context: 100 curated variables derived from unstructured data sources.
• Tailored Cohort Design: Customer-defined inclusion and exclusion criteria to match specific research protocols.
• Flexible Study Execution: Ready for protocol-driven analytics or sponsor-led studies.
• Fast, Refreshable Delivery: Delivery as fast as 14 weeks, with quarterly refresh capability.

Featured Publications

• Oncology trial emulation using real-world electronic health record data: Results of the Coalition to Advance Real-World Evidence through Randomized Controlled Trial Emulation (CARE) initiative.
• Real-world adjuvant nivolumab utilization in surgically treated muscle-invasive bladder cancer patients within U.S. community oncology practice.
• Adjusted comparison of amivantamab in combination with carboplatin plus pemetrexed from the PAPILLON study versus U.S. real-world frontline treatments in patients with advanced NSCLC harboring EGFR exon 20 insertions.

Patient360™ is offered by ConcertAI as part of its broader Precision Suite of oncology data and analytics solutions. The platform is designed to serve as a foundational asset for life sciences sponsors, research organizations, and health systems seeking to accelerate evidence generation, optimize clinical trial design, and improve understanding of real-world cancer care delivery across the United States.